Contemporary management of pediatric heart failure

Expert Review of Cardiovascular Therapy

Volumn 6, Issue 2, 2008, Pages 187-197

  Margossian, Renee ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

blocker; Angiotensin converting enzyme inhibitor; Heart failure; Levosimendan; Pediatric; Resynchronization

Indexed keywords

ADRENALIN; ALDOSTERONE ANTAGONIST; AMRINONE; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARDIAC GLYCOSIDE; CARVEDILOL; CATECHOLAMINE; CYCLIC AMP; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOBUTAMINE; ENALAPRIL; EPLERENONE; GLYCERYL TRINITRATE; LEVOSIMENDAN; LISINOPRIL; METOPROLOL; MILRINONE; NESIRITIDE; NORADRENALIN; PHOSPHODIESTERASE III; PHOSPHODIESTERASE INHIBITOR; PLACEBO; POTASSIUM CHLORIDE; SPIRONOLACTONE;

ACUTE HEART FAILURE; CARDIAC RESYNCHRONIZATION THERAPY; CHILD; CHILD CARE; CHRONOTROPISM; CLINICAL FEATURE; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; COUGHING; DEFIBRILLATOR; DISEASE CLASSIFICATION; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG TOLERABILITY; ECHOCARDIOGRAPHY; ELECTROLYTE DISTURBANCE; GYNECOMASTIA; HEART ASSIST DEVICE; HEART CATHETERIZATION; HEART FAILURE; HEART LEFT RIGHT SHUNT; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE BIOPSY; HEART SURGERY; HEART TRANSPLANTATION; HUMAN; HYPOKALEMIA; HYPOTENSION; LOW DRUG DOSE; METABOLIC ALKALOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; THORAX RADIOGRAPHY; UNSPECIFIED SIDE EFFECT; CARDIOLOGY; HEART VENTRICLE FUNCTION; INCIDENCE;

CARDIOLOGY; CHILD; HEART FAILURE; HUMANS; INCIDENCE; VENTRICULAR FUNCTION;

EID: 40149088839     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.6.2.187     Document Type: Review

References (64)

1. Galbreath AD, Krasuski RA, Smith B et al. Long-term healthcare and cost outcomes of disease management in a large, randomized, community-based population with heart failure. Circulation 110, 3518-3526 (2004).
2. Kannel WB. Incidence and epidemiology of heart failure. Heart Failure Rev. 5, 167-173 (2000).
3. Lipshultz SE, Sleeper LA, Towbin JA et al. The incidence of pediatric cardiomyopathy in two regions of the United States. N. Engl. J. Med. 348, 1647-1655 (2003).
4. Nugent AW, Daubeney PEF, Chondros P et al. The epidemiology of childhood cardiomyopathy in Australia. N. Engl. J. Med. 348, 1639-1646 (2003).
5. Katz AM. Heart Failure. In: Pathophysiology, Molecular Biology and Clinical Management. Lippincott, Williams & Wilkins, PA, USA, xiii (2000).
6. Francis GS, McDonald K, Chu C, Cohn JN. Pathophysiologic aspects of end-stage heart failure. Am. J. Cardiol. 75, 11A-18A, (1995).
7. Fenton M, Burch M. Understanding chronic heart failure. Arch. Dis. Child. 92, 812-816 (2007).
8. Mann DL, Bristow MR. Mechanisms and models in heart failure: the biomechanical model and beyond. Circulation 111, 2837-2849 (2005).
9. Mir TS, Maroh S, Laer S, Eiselt M, Grollmus O, Weil J. Plasma concentration of N-terminal and pro-brain natriuretic peptide in control children from the neonatal to adolescent period and in children with congestive heart failure. Pediatrics 110, e76, (2002).
10. Guimaraes GV, Bellotti G, Mocelin AO et al. Cardiopulmonary exercise testing in children with heart failure secondary to idiopathic dilated cardiomyopathy. Chest 120, 816-824 (2001).
11. Ross RD, Bollinger RO, Pinsky WW. Grading the severity of heart failure in Infants. Pediatr. Cardiol. 13, 72-75 (1992).
12. Johnstone DE, Abdulla A, Arnold JM et al. Diagnosis and management of heart failure. Canadian Cardiovascular Society. Can. J. Cardiol. 10, 613-631 (1994).
13. Connolly D, Rutkowski M, Auslender M, Artman M. The New York University Pediatric Heart Failure Index: a new method of quantifying chronic heart failure severity in children. J. Pediatr. 138, 644-648 (2001).
14. Hunt SA, Baker DW, Chin MH et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure) J. Am. Coll. Cardiol. 38, 2101-21013 (2001).
15. Rosenthal D, Chrisant MRK, Edens E et al. International Society for Heart and Lung Transplantation: Practice Guidelines for Management of Heart Failure in Children. J. Heart Lung Transplant. 23, 1313-1333 (2004).
16. Haykowsky MJ, Liang Y, Pechter D et al. A meta-analysis of the effect of exercise training on left ventricular remodeling in heart failure patients: The benefit depends on the type of training performed. J. Am. Coll. Cardiol. 49, 2329-2336 (2007).
17. Blume ED, Freed MD, Colan SD. Congestive Heart Failure. In: Nadas' Pediatric Cardiology, 2nd Edition. Keane JF, Lock JE, Fyler DC (Eds). Saunders Elsevier Publishers, PA, 83-95 (2006).
18. Moffett BS and Chang AC. Future pharmacologic agents for treatment of heart failure in children. Pediatr. Cardiol. 27, 533-551 (2006).
19. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study. N. Engl. J. Med. 316, 1429-1435 (1987).
20. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N. Engl. J. Med. 325, 293-302 (1991).
21. Packer M, Poole-Wilson PA, Armstrong PW et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 100, 2312-2318 (1999).
22. Lewis AB, Chabot M. The effect of treatment with angiotensin-converting enzyme inhibitors on survival of pediatric patients with dilated cardiomyopathy. Pediatr. Cardiol. 14, 9-12 (1993).
23. Lin M, Chiang HT, Lin SL et al. Vasodilator therapy in chronic asymptomatic aortic regurgitation: enalapril versus hydralazine therapy. J. Am. Coll. Cardiol. 24, 1046-1053 (1994).
24. Evangelista A, Tornos P, Sambola A, Permanyer-Miralda G, Soler-Soler J. Long-term vasodilator therapy in patients with severe aortic regurgitation. N. Engl. J. Med. 353, 1342-1349 (2005).
25. Mori Y, Nakazawa M, Tomimatsu H, Momma K. Long-term effect of angiotensin-converting enzyme inhibitor in volume overloaded heart during growth: a controlled pilot study. J. Am. Coll. Cardiol. 36, 270-275 (2000).
26. Rheuban KS, Carpenter MA, Ayers CA, Gutgesell HP. Acute hemodynamic effects of converting enzyme inhibition in infants with congestive heart failure. J. Pediatr. 117, 668-670 (1990).
27. Burnier M. Angiotensin II type 1 receptor blockers. Circulation 103, 904-912 (2001).
28. Jong P, Demers, C, McKelvie RS, Liu PP. Angiotensin receptor blockers in heart failure: meta-analysis of randomized controlled trials. J. Am. Coll. Cardiol. 39, 463-470 (2002).
29. Dimopoulos K, Salukhe TV, Coats AJS, Mayer J, Piepoli M, Francis DP. Meta-analyses of mortality and morbidity effects of an angiotensin receptor blocker in patients with chronic heart failure already receiving an ACE inhibitor (alone or with a beta-blocker). Int. J. Cardiol. 93, 105-111 (2004).
30. Hjalmarson A, Goldstein S, Fagerberg B et al. Effects of controlled-release metoprolol on total mortality, hospitalizations and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). JAMA 283, 1295-1302 (2000).
31. Packer M, Coats AJ, Fowler MB et al. Effect of carvedilol on survival in severe chronic heart failure. N. Engl. J. Med. 344, 1651-1658 (2001).
32. Shaddy RE, Tani LY, Gidding SS et al. Beta-blocker treatment of dilated cardiomyopathy with congestive heart failure in children: a multi-institutional experience. J. Heart Lung Transplant. 18, 269-274 (1999).
33. Bruns LA, Chrisant MK, Lamour JM et al. Carvedilol as therapy in pediatric heart failure: an initial multicenter experience. J. Pediatr. 138, 505-511 (2001).
34. Shaddy RE, Boucek MM, Hsu DT et al. Carvedilol for children and adolescents with heart failure: a randomized controlled trial. JAMA 298, 1171-1179 (2007).
35. Kouatli AA, Garcia JA, Zellers TM, Weinstein EM, Mahony L. Enalapril does not enhance exercise capacity in patients after Fontan procedure. Circulation 96, 1507-1512 (1997).
36. Dore A, Houde C, Chan KL et al. Angiotensin receptor blockade and exercise capacity in adults with systemic right ventricles: a multicenter, randomized, placebo-controlled clinical trial. Circulation 112, 2411-2416 (2005).
37. Laer, S, Mir TS, Behn F et al. Carvedilol therapy in pediatric patients with congestive heart failure: a study investigating clinical and pharmacokinetic parameters. Am. Heart J. 145, 916-922 (2002).
38. Gidding SS. The importance of randomized controlled trials in pediatric cardiology. JAMA 298, 1214-1216, (2007).
39. Hunt SA, Abraham WT, Chin MH et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing committee to update the 2001 guidelines for the evaluation and management of heart failure). Circulation 112, e154-e235 (2005).
40. Mano A, Tatsumi T, Shiraishi J et al. Aldosterone directly induces myocyte apoptosis through calcineurin-dependent pathways. Circulation 110, 317-323 (2004).
41. MacFadyen RJ, Lee AFC, Morton JJ, Pringle SD, Struther AD. How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure? Heart 82, 57-61 (1999).
42. Pitt B, Zannad P, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N. Engl J. Med. 341, 709-717 (1999).
43. Pitt B, Remme W, Zannad F et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. Med. 348, 1309-1321 (2003).
44. Ferguson DW, Berg WJ, Sanders JS, Roach PJ, Kempf JS, Kienzle MG. Sympathoinhibitory responses to digitalis glycosides in heart failure patients: direct evidence from sympathetic neural recordings. Circulation 80, 65-77 (1989).
45. Covit AB, Schaer GI, Sealey JE, Laragh JH, Cody RJ. Suppression of the renin-angiotensin system by intravenous digoxin in chronic congestive heart failure. Am. J. Med. 75, 445-447 (1983).
46. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N. Engl J. Med. 336, 525-533 (1997).
47. Kimball TR, Daniels SR, Meyer et al. Effect of digoxin on contractility and symptoms in infants with a large ventricular septal defect. Am. J. Cardiol. 68, 1377-1382 (1991).
48. Latifi S, Lidsky K, Blumer JL. Pharmacology of inotropic agents in infants and children. Prog. Pediatr. Cardiol. 12, 57-79 (2000).
49. Hoffman TM, Wernovsky G, Atz AM et al. Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease. Circulation 107, 996-1002 (2003).
50. Habib DM, Padbury JF, Anas NG,-Perkin RM, Minegar C. Dobutamine pharmacokinetics and pharmacodynamics in pediatric intensive care patients. Crit. Care Med. 20, 601-608 (1992).
51. Wessel DL. Testing new drugs for heart failure in children. Pediatr. Crit. Care Med. 7, 493-494 (2006).
52. Publication Committee for the VMAC Investigators. Intravenous nesiritide vs Nitroglycerin for treatment of decompensated congestive heart failure; a randomized controlled trial. JAMA 287, 1531-1540 (2002).
53. Mahle WT, Cuadrado AR, Kirshom PM, Kanter KR, Simsic JM. Nesiritide in infants and children with congestive heart failure. Pediatr. Crit. Care Med. 6, 543-546 (2005).
54. Tassani P, Schad H, Heimisch W et al. Effect of the calcium sensitizer levosimendan on the performance of ischaemic myocardium in anaesthetized pigs. Cardiovasc. Drugs Ther. 16, 35-41 (2002).
55. Adamopoulos S, Parissis JT, Iliodromitis EK et al. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. Am. J. Cardiol. 98, 102-206 (2006).
56. Follath F, Cleland JGF, Just H et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomized double-blind trial. Lancet 360, 196-202 (2002).
57. Namachivayam P, Crossland DS, Butt WW, Shekerdemian LS. Early experience with levosimendan in children with ventricular dysfunction. Pediatr. Crit. Care Med. 7, 445-448 (2006).
58. Mebazaa A, Nieminen MS, Packer M et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA 297, 1883-1891 (2007).
59. Young JB, Abraham WT, Smith AL et al. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD trial. JAMA 289, 2685-2694 (2003).
60. Bristow MR, Saxon LA, Boehmer J et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N. Engl. J. Med. 350, 2140-2150 (2004).
61. Dubin AM, Janousek J, Rhee E et al. Resynchronization therapy in pediatric and congenital heart disease patients. J. Am. Coll. Cardiol. 46, 2277-2283 (2005).
62. Potapov EV, Stiller B, Hetzer R. Ventricular assist devices in children: current achievements and future perspectives. Pediatr. Transplantation 11, 241-155 (2007).
63. Boucek MM, Edwards LB, Keck BM et al. Registry for the International Society for Heart and Lung Transplantation: seventh official pediatric report 2004. J Heart Lung Transplant. 23, 933-947 (2004).
64. Anand IS, Florea VG, Fisher L. Surrogate end points in heart failure. J. Am. Coll. Cardiol. 39, 1414-1421 (2002).